Anosmin Antibody | 6367

Anosmin Antibody | 6367 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human

Homology: N/A

Immunogen: Anosmin antibody was raised against an 18 amino acid synthetic peptide near the center of human Anosmin.
The immunogen is located within amino acids 430 - 480 of Anosmin.

Research Area: Signal Transduction

Tested Application: E, WB, ICC, IF

Application: Anosmin antibody can be used for detection of Anosmin by Western blot at 1 μg/mL. Antibody can also be used for immunocytochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in human samples; Immunocytochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.

Specificiy: N/A

Positive Control 1: Cat. No. 1219 - MCF7 Cell Lysate

Positive Control 2: Cat. No. 17-012 - MCF7 Cell Slide

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: Anosmin Antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: Anosmin Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: Anosmin antibody can be stored at 4 ˚C, stable for one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: Anosmin Antibody: HH1, HHA, KAL, KMS, ADMLX, WFDC19, KALIG-1, KALIG1, Anosmin-1, Adhesion molecule-like X-linked

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: Anosmin Antibody: Mutations in Anosmin-1, an extracellular matrix-associated glycosylated protein, have been linked with Kallmann Syndrome (KS) , an X-linked genetic disorder characterized by loss of smell caused by abnormal olfactory bulb development and delayed puberty caused by disrupted migration of the gonadotropin-releasing hormone neuron. Anosmin-1 has been shown to directly bind FGFR1 via its N-terminal cysteine-rich domain, whey-acidic protein-like domain, and its first FnIII repeat with the D2 and D3 ectodomains of FGFR1. It is thought that Anosmin-1 can modulate FGFR1 signaling and have opposing effects on the formation and activation of FGF2-FGFR1-heparing complex.